In a controversial move, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has announced investigations into the potential link between psychiatric medications and violent behavior, following a recent school shooting involving a transgender individual. The announcement comes amid growing scrutiny of the role of antidepressants, particularly SSRIs, in exacerbating mental health crises.

Kennedy, appearing on Fox News, framed mass shootings as a “health crisis” and disclosed that his department will explore how over-reliance on psychiatric drugs, including Selective Serotonin Reuptake Inhibitors (SSRIs), may contribute to violent incidents. He cited the recent massacre at Annunciation Catholic School, where shooter Robin Westman was taking medications during his gender transition, as a focal point for inquiry.

The investigation will examine whether drugs like SSRIs—commonly prescribed for depression and anxiety—could be linked to increased aggression or suicidal ideation. Over 30 million Americans are currently on antidepressants, with SSRIs being the most frequently prescribed class. Data from 2015–2018 showed 13.2% of U.S. adults used antidepressants, a figure that has risen sharply in recent years, particularly among women and older adults.

Kennedy also referenced another transgender school shooter, Audrey Hale, to underscore his concerns about the intersection of gender transition medications and violence. However, he did not confirm whether Westman or Hale were taking specific drugs at the time of their actions. The secretary emphasized the need for transparency, noting that patient confidentiality rules have hindered previous research but that his department has authority to override such restrictions in public health investigations.

The move has sparked debate over pharmaceutical accountability and the broader implications of mental health treatment policies. Critics argue that the focus on drug-related violence risks stigmatizing vulnerable populations, while supporters demand greater oversight of the medical industry.